Results 41 to 50 of about 3,780 (219)

Synthesis of Various Dihydro–Thiazole and Selenazole Heterocycles

European Journal of Organic Chemistry, Volume 27, Issue 43, November 18, 2024.
The synthesis of thiazole derivatives was achieved by reacting I2/SCN− with various push‐pull alkenes. The substitution followed by intramolecular cyclization under mild conditions resulted in the desired products. When KSeCN was used, a selenazole derivative was formed.
Mihály Viktor Pilipecz, Tamás Róbert Varga, Zoltán Vincze, Gitta Schlosser, Dávid Papp, András Simon, Zoltán Mucsi, Péter Nemes   +7 more
wiley   +1 more source

Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome [PDF]

, 2008
Somatostatin (SS) and dopamine (DA) receptors are widely expressed in neuroendocrine tumours that cause Cushing's Syndrome (CS). Increasing knowledge of specific subtype expression within these tumours and the ability to target these receptor subtypes ...
A Colao, A Colao, A Newman-Tancredi, A Saiardi, A Saveanu, A Saveanu, A Schonbrunn, AB Atkinson, AM Isidori, AM O’Carroll, AS Mahmoud-Ahmed, B Ambrosi, B Ueberberg, C Bruns, C Garcia, C Invitti, C Missale, C Missale, C. de Bruin, D Cervia, D Cervia, D Ferone, D Gaitan, D Morris, D Yin, DC Danila, DL Batista, DN Orth, DW Ray, E Mezey, F Amenta, F Castinetti, F Illouz, F Kelestimur, F Vignati, G Giustina, G Weckbecker, GI Uwaifo, GK Stalla, HA Schmid, HA Schmid, HL Fehm, I Ilias, I Shraga-Slutzky, J Hoek van der, J Hoek van der, J Jagannathan, J Kraicer, J Lindholm, J Newell-Price, J Stack, JB Tyrrell, JC Reubi, JM Farah Jr., JW Miller, KD Wu, L Petrini, L Stefaneanu, L. J. Hofland, LA Casulari, LJ Hofland, LJ Hofland, LJ Hofland, LK Nieman, M Locatelli, M Phlipponneau, M Rocheville, M Tallent, ME Molitch, ML Vance, MR Brown, MZ Strowski, N Unger, N Unger, P Barnett, P Brazeau, P Jaquet, P Jaquet, P Ma, P Petrossians, PJ Stafford, R Day, R Hall, R Pivonello, R Pivonello, R Pivonello, R Pivonello, R Pivonello, R Pivonello, R Pivonello, R Schade, R Zanettini, R. A. Feelders, RJ Benveniste, RJ Croughs, S. W. J. Lamberts, SL Lightman, SW Lamberts, SW Lamberts, SW Lamberts, SW Lamberts, SW Lamberts, SW Lamberts, SW Lamberts, SW Lamberts, SW Lamberts, SW Lamberts, T Antakly, T Miyoshi, UI Richardson, VG Rasmussen, WE Farrell, WW Herder de, WW Herder de, X Bertagna, YC Patel   +115 more
core   +4 more sources

Patients' perspective on their drug therapy after bariatric surgery: A quantitative, cross‐sectional interview study

Clinical Obesity, Volume 14, Issue 5, October 2024.
Graphical abstract on the background, methods, summarized results and conclusion of the study. Summary Drug therapy in patients who have undergone bariatric surgery is challenging. We aimed to investigate the patients' perspective on their drug therapy.
Susanne Schiek, Melissa Drotleff, Dorit Schueler, Katrin Heinitz, Annett Frisch, Lars Selig, Yvonne Remane, Arne Dietrich, Matthias Blüher, Thilo Bertsche   +9 more
wiley   +1 more source

Cyclopentenyl ethylamines active on CNS [PDF]

, 1992
Two new cyclopentenylethylamines were prepared and were submitted to a pharmacological screening together with some others previously described and now reprepared. All compounds exhibited different degrees of depressive activity on CNS and good analgesic
Dimich, P.M., Moretti, Mario Domenico Luigi, Mulè, Antonio Calogero, Peana, Alessandra Tiziana, Pirisino, Gerolamo Antonio, Satta, Margherita, Sparatore, Fabio   +6 more
core  

Virtual Affinity Fingerprints for Target Fishing: A New Application of Drug Profile Matching [PDF]

, 2013
We recently introduced Drug Profile Matching (DPM), a novel virtual affinity fingerprinting bioactivity prediction method. DPM is based on the docking profiles of ca.
Czobor, P., Hári, P., Jelinek, B., Málnási Csizmadia, András, Peragovics, Á., Simon, Z., Tombor, L.   +6 more
core   +1 more source

Prevalence of Late‐Stage Parkinson's Disease in the US Healthcare System: Insights from TriNetX

Movement Disorders, Volume 39, Issue 9, Page 1592-1601, September 2024.
Abstract Background Patients in late‐stage Parkinson's disease (PDLS) are caregiver‐dependent, have low quality of life, and higher healthcare costs. Objective To estimate the prevalence of PDLS patients in the current US healthcare system. Methods We downloaded the 2010–2022 data from the TriNetX Diamond claims network that consists of 92 US ...
Sol De Jesus, Annika Daya, Liba Blumberger, Mechelle M. Lewis, Doug Leslie, Samer D. Tabbal, Rachel Dokholyan, Amanda M. Snyder, Richard B. Mailman, Xuemei Huang   +9 more
wiley   +1 more source

Depression in Parkinson's disease [PDF]

, 2014
The prevalence of major and minor depression in Parkinson’s disease is around 30–40% but, unfortunately, depression remains frequently underrecognized and often undertreated.
Döme, Péter, Gonda, Xénia, Rihmer, Zoltán   +2 more
core  

Heterogeneous treatment effects of sodium‐glucose cotransporter 2 inhibitors on risk of dementia in people with type 2 diabetes: A population‐based cohort study

Alzheimer's &Dementia, Volume 20, Issue 8, Page 5528-5539, August 2024.
Abstract INTRODUCTION Sodium‐glucose cotransporter 2 (SGLT2) inhibitors exhibit potential benefits in reducing dementia risk, yet the optimal beneficiary subgroups remain uncertain. METHODS Individuals with type 2 diabetes (T2D) initiating either SGLT2 inhibitor or sulfonylurea were identified from OneFlorida+ Clinical Research Network (2016–2022).
Huilin Tang, William T. Donahoo, Mikael Svensson, C. Elizabeth Shaaban, Glenn Smith, Michael S. Jaffee, Yu Huang, Xia Hu, Ying Lu, Ramzi G. Salloum, Steven T. DeKosky, Jiang Bian, Jingchuan Guo   +12 more
wiley   +1 more source

Optimal dose for the efficacy of asenapine in patients with schizophrenia: Real‐world data

Neuropsychopharmacology Reports, Volume 44, Issue 1, Page 234-239, March 2024.
A meta‐analysis of large short‐term studies found no significant difference between asenapine doses of 10 and 20 mg/day for acute schizophrenia treatment. However, these studies' homogeneous patient populations may not accurately represent the diversity seen in clinical practice.
Yoshiteru Takekita, Shuichi Hiraoka, Yasuhiro Iwama, Daisuke Matsui, Nobuatsu Aoki, Haruhiko Ogata, Toshiya Funatsuki, Toshiyuki Shimizu, Yuji Murase, Yosuke Koshikawa, Masaki Kato, Toshihiko Kinoshita   +11 more
wiley   +1 more source

Prescribing cascades in ambulatory care: A structured synthesis of evidence

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 44, Issue 1, Page 87-96, January 2024.
Abstract The strength of evidence for specific ambulatory care prescribing cascades, in which a marker drug is used to treat an adverse event caused by an index drug, has not been well characterized. To perform a structured, systematic, and transparent review of the evidence supporting ambulatory care prescribing cascades.
Faiza Shahid, Ann Doherty, Emma Wallace, Sven Schmiedl, G. Caleb Alexander, Tobias Dreischulte   +5 more
wiley   +1 more source